MIRA

MKT CAP:$45M

MIRA Pharmaceuticals, Inc.

Market Cap

$45M

Healthcare·Drug Manufacturers - General·🇺🇸 United States·NASDAQ

Healthcare·Drug Mfg.·🇺🇸·NASDAQ

Stock Price

$1.05-$0.44 (-29.53%)

Apr 23, 2026

Company Details

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company focuses on the development and commercialization of a new molecular synthetic tetrahydrocannabinol (THC) analog under investigation f...

CEO

Erez Aminov

IPO Date

Aug 14, 2023

Website

mirapharmaceuticals.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$28M

EPS (Diluted)

-$1.54

Free Cash Flow

-$5M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

FY 2025

Mar 31, 2026

$0EPS -$1.35

Q3 2025

Nov 13, 2025

$0EPS -$1.18

Q2 2025

Aug 14, 2025

$0EPS -$0.09

Q1 2025

May 14, 2025

$0EPS -$0.11

FY 2024

Apr 17, 2025

$0EPS -$0.51

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$0	$0	-$52.1K
Q1 22	$0	$0	-$1M
Q2 22	$0	$0	-$2M
Q3 22	$0	$0	-$2M
Q4 22	$0	$0	-$1M
Q1 23	$0	$0	-$1M
Q2 23	$0	$0	-$970.2K
Q3 23	$0	$0	-$3M
Q4 23	$0	$0	-$3M
Q1 24	$0	$0	-$2M
Q2 24	$0	$0	-$2M
Q3 24	$0	$0	-$2M
Q4 24	$0	$0	-$2M
Q1 25	$0	$0	-$2M
Q2 25	$0	$0	-$2M
Q3 25	$0	$0	-$1M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 21	-$16.4K	-$16.4K
Q1 22	-$2M	-$2M
Q2 22	-$1M	-$1M
Q3 22	-$1M	-$1M
Q4 22	-$975.4K	-$975.4K
Q1 23	-$1M	-$1M
Q2 23	-$660.8K	-$660.8K
Q3 23	-$2M	-$2M
Q4 23	-$2M	-$2M
Q1 24	-$1M	-$1M
Q2 24	-$863.9K	-$863.9K
Q3 24	-$2M	-$2M
Q4 24	-$2M	-$2M
Q1 25	-$2M	-$2M
Q2 25	-$799.7K	-$799.7K
Q3 25	-$1M	-$1M

Capital Expenditures

Quarter	CapEx
Q1 21	$0
Q1 22	$0
Q2 22	$0
Q3 22	$0
Q4 22	$0
Q1 23	$4
Q2 23	$3
Q3 23	$0
Q4 23	$1
Q1 24	$4
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$3
Q2 25	$0
Q3 25	$4

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	—	+2489.1%
Q1 23	—	-9.0%
Q2 23	—	-59.9%
Q3 23	—	+74.7%
Q4 23	—	+126.8%
Q1 24	—	+32.0%
Q2 24	—	+78.4%
Q3 24	—	-34.1%
Q4 24	—	-20.2%
Q1 25	—	+2.1%
Q2 25	—	-10.7%
Q3 25	—	-36.7%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 21	$0	—
Q1 22	$0	—
Q2 22	$1M	—
Q3 22	$147.8K	—
Q4 22	$147.8K	—
Q1 23	$147.8K	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$0	—
Q1 24	$500.2K	—
Q2 24	$604.8K	—
Q3 24	$269.0K	—
Q4 24	$546.8K	—
Q1 25	$874.8K	—
Q2 25	$489.6K	—
Q3 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 21	$33.7K	$18.3K	—	—
Q1 22	$479.1K	$617.2K	—	—
Q2 22	$269.4K	$2M	—	—
Q3 22	$715.0K	$736.1K	—	—
Q4 22	$884.8K	$51.7K	$411.3K	—
Q1 23	$271.6K	$614.2K	—	—
Q2 23	—	$1M	—	—
Q3 23	$1M	$2M	—	—
Q4 23	$387.1K	$3M	—	—
Q1 24	$762.3K	$1M	—	—
Q2 24	$614.5K	$1M	—	—
Q3 24	$1M	$1M	—	—
Q4 24	$861.4K	$2M	—	—
Q1 25	$314.4K	$1M	—	—
Q2 25	$496.2K	$1M	—	—
Q3 25	$412.6K	—	—	$904.3K

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 21	$0	$0	$0
Q1 22	$2M	$0	$2M
Q4 22	$351.0K	$0	$351.0K
Q1 23	$1.3K	$0	$1.3K
Q2 23	$24.8K	$0	$24.8K
Q3 23	$6M	$0	$6M
Q4 23	$5M	$0	$5M
Q1 24	$4M	$0	$4M
Q2 24	$3M	$0	$3M
Q3 24	$4M	$0	$4M
Q4 24	$3M	$0	$3M
Q1 25	$1M	$0	$1M
Q2 25	$730.5K	$0	$730.5K
Q3 25	$3M	$0	$3M
Q4 25	$6M	$0	$6M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	15M	—	—
Q1 22	15M	0.0%	—
Q2 22	15M	0.0%	—
Q3 22	15M	0.0%	—
Q4 22	15M	0.0%	0.0%
Q1 23	15M	0.0%	0.0%
Q2 23	15M	+0.2%	+0.2%
Q3 23	15M	0.0%	+0.2%
Q4 23	15M	0.0%	+0.2%
Q1 24	20M	+33.3%	+33.7%
Q2 24	15M	-25.0%	0.0%
Q3 24	15M	+2.0%	+2.0%
Q4 24	15M	+2.5%	+4.5%
Q1 25	17M	+7.8%	-15.5%
Q2 25	17M	+2.1%	+14.9%
Q3 25	19M	+13.5%	+27.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	—	—
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	3
Q1 24	$0	3
Q2 24	$0	3
Q3 24	$0	3
Q4 24	$0	5
Q1 25	$0	5
Q2 25	$0	5
Q3 25	$0	5

Revenue / Employee